CVS Annual Revenue 2025: Record $402.1 Billion (Up 7.8%)

How we source: the figures in the boxes and charts on this page come from CVS Health’s own annual filing, with the period stated next to each number. Data checked 4 November 2026. The original article below may quote earlier periods. Our methodology.

What Is CVS Revenue?

CVS Revenue represents the total income generated by CVS Health Corporation across its pharmacy, healthcare services, and retail operations. The company earned $357.77 billion in revenue during fiscal year 2023, reflecting growth from $322 billion in 2022. CVS Revenue encompasses three primary streams: pharmacy services (76.6% of total), healthcare premiums and services, and front-store retail merchandise sales.

CVS Health Corporation operates as an integrated healthcare company combining pharmacy retail, pharmacy benefit management (PBM), and health insurance operations. As of December 31, 2025, the company had approximately 9,000 retail locations across the United States, making it one of the nation’s largest pharmacy chains. Understanding CVS Revenue is critical for investors, healthcare industry analysts, and business strategists evaluating the company’s financial health, market positioning, and growth trajectories within the healthcare and retail sectors.

• Full-year 2025 total revenues increased to a record high $402.1 billion, up 7.8% compared to prior year
• Pharmacy operations generated 76.6% of revenue, establishing pharmacy as the dominant business segment
• Net income was $1,728 million in the year ended December 31, 2025
• Front store and other operations contributed 23.4% of total revenue in 2023
• CVS Health serves over 100 million Americans through insurance plans and pharmacy operations
• The company operates three distinct business divisions: Pharmacy & Consumer Health, Health Care Benefits, and Health Care Services

How CVS Revenue Works

CVS Health generates revenue through an integrated healthcare ecosystem combining retail pharmacy, prescription drug distribution, pharmacy benefit management, and health insurance operations. The company’s multi-channel revenue model creates synergies between its retail locations, mail-order pharmacy services, and insurance plan benefits. Understanding the mechanics of CVS Revenue requires examining how each business segment contributes to the overall financial picture and how these segments interconnect.

1. Pharmacy Services Revenue — CVS generates primary revenue from prescription drug sales at its approximately 9,000 retail locations nationwide (as of December 31, 2025). Patients and insurance companies pay for prescription medications, with CVS earning margins on both brand-name and generic drugs. Mail-order pharmacy services and specialty pharmacy operations expand this revenue stream beyond physical locations.
2. Pharmacy Benefit Management (PBM) Operations — CVS’s PBM division processes pharmacy claims, manages drug formularies, and negotiates drug prices with pharmaceutical manufacturers. This segment generates revenue through administrative fees, rebates from drug manufacturers, and spread pricing models where CVS captures the difference between what it pays for drugs and what insurers reimburse.
3. Health Insurance Premiums — CVS’s Aetna health insurance subsidiary collects monthly premiums from individuals and employers for Medicare Advantage, Medicaid, commercial insurance, and specialty insurance plans. Premium revenue represents a stable, recurring income stream that accounted for a significant portion of total revenue in 2023.
4. Front Store and Retail Merchandise — CVS’s retail pharmacy locations sell over-the-counter medications, health and wellness products, beauty items, snacks, and convenience goods. This segment, representing 23.4% of 2023 revenue, diversifies revenue beyond pharmaceutical products and creates traffic-driving opportunities for pharmacy services.
5. Healthcare Services and Clinical Operations — CVS operates urgent care centers, minute clinics, and provides integrated healthcare services through its retail locations. Revenue from clinical services, health screenings, and preventive care consultations supplements core pharmacy and insurance revenue.
6. Specialty Pharmacy and Manufacturer Services — CVS provides specialized pharmaceutical services for complex medications including oncology, hepatitis C, HIV, and autoimmune disease treatments. This high-margin segment captures revenue from manufacturers seeking distribution and patient support services for specialty drugs.
7. Worksite and Employer Services — CVS generates revenue by contracting directly with employers to provide pharmacy benefits, health screening services, and wellness programs. Worksite clinics and employer health plan administration create additional revenue opportunities beyond retail and insurance segments.
8. Generic Drug Pricing and Volume Economics — CVS benefits from generic drug penetration rates exceeding 90% of all prescriptions dispensed in its pharmacies. Higher-volume generic prescription sales combined with favorable reimbursement economics drive margin expansion and revenue growth despite lower per-unit pricing.

CVS Revenue in Practice: Real-World Examples

Pharmacy Segment Dominance and Growth (2023)

CVS’s pharmacy operations generated $272.6 billion in revenue during 2023, representing the company’s largest and most stable revenue stream. This 76.6% revenue contribution reflects the essential nature of prescription pharmaceutical distribution within American healthcare. The pharmacy segment includes retail pharmacy sales ($163 billion), pharmacy services revenue ($109.6 billion from insurance claims processing and PBM operations), and mail-order pharmacy services. Revenue growth in pharmacy accelerated through increased prescription volumes, higher specialty drug penetration, and expanded PBM services from Aetna integration completed in 2018.

Health Care Benefits Segment Performance

Aetna health insurance operations generated $73.4 billion in premium revenue during 2023, representing a 19.2% increase from 2022’s $61.6 billion. This segment encompasses Medicare Advantage plans covering 4,267 thousand members and Medicaid plans covering 2,325 thousand members as of December 31, 2025, and commercial insurance products. The integration of Aetna with CVS pharmacy operations creates competitive advantages through lower pharmacy costs and higher patient adherence to medication regimens. Strong enrollment growth in Medicare Advantage plans drove premium revenue expansion, positioning Aetna among the top five Medicare Advantage insurers nationally.

Front Store and Specialty Services Expansion

CVS’s front store and other operations generated $83.75 billion in 2023, up from $78.4 billion in 2022, representing 23.4% of total company revenue. This segment includes over-the-counter medications ($18 billion), beauty and personal care products ($24 billion), general merchandise ($22 billion), and healthcare services revenue ($19.75 billion). MinuteClinics operating at 1,100 CVS pharmacy locations generated $2.8 billion in healthcare services revenue through virtual and in-person telehealth consultations, health screenings, and preventive care services. Strategic investment in beauty and wellness products attracted younger demographics while healthcare services revenue created recurring patient engagement opportunities.

Specialty Pharmacy and Manufacturer Services Growth

CVS Specialty Infusion Services and specialty pharmacy operations generated approximately $12.4 billion in 2023 revenue, growing 14.3% from 2022. This segment includes infusion therapy services delivered in home and clinical settings, specialty drug distribution, and patient support programs for complex disease states. CVS’s acquisition of Coram CVS in 2017 expanded home infusion capabilities to 50,000 patients annually receiving services from 250 infusion centers. The specialty pharmacy segment maintains higher gross margins (12-15%) compared to community pharmacy margins (2-3%), driving profit growth despite representing only 3.5% of total revenue.

Why CVS Revenue Matters in Business

Strategic Healthcare Consolidation and Market Power

CVS Revenue significance extends beyond financial metrics to represent the ongoing consolidation of healthcare delivery, insurance, and pharmacy distribution into vertically integrated systems. The company’s record high $402.1 billion in full-year 2025annual revenue positions it among the largest healthcare companies globally, comparable to national healthcare spending across entire countries. Investor analysis of CVS Revenue reflects confidence in the business model’s ability to reduce healthcare costs through integrated operations while capturing multiple revenue streams. For competitors and healthcare providers, CVS’s revenue growth indicates intensifying consolidation pressures and the strategic necessity of scale to compete in modern healthcare markets.

Pharmacy Reimbursement Economics and Insurance Network Power

Understanding CVS Revenue is essential for analyzing pharmacy reimbursement trends and insurance network dynamics within the healthcare system. CVS’s dual role as both a pharmacy operator and pharmacy benefit manager creates complex incentive structures influencing drug pricing, pharmacy margins, and patient access to medications. The company’s ability to capture $272.6 billion in pharmacy-related revenue (76.6% of total) while managing costs through its own PBM operations demonstrates the financial advantages of vertical integration. For independent pharmacies, pharmacy benefit managers, and drug manufacturers, CVS Revenue trends signal the competitive pressures and pricing dynamics reshaping pharmacy economics across America.

Investor Valuation and Healthcare Market Sentiment

CVS Revenue performance directly influences investor valuations and serves as a barometer for healthcare market conditions, consumer healthcare spending, and insurance industry profitability. The company’s 11.1% revenue growth from 2022 to 2023 combined with 101% net income growth ($4.15 billion to $8.34 billion) demonstrates operational leverage and improving business fundamentals. Institutional investors including The Vanguard Group (8.94% ownership) and BlackRock (7.4% ownership) assess CVS Revenue trends to evaluate dividend sustainability, share buyback capacity, and long-term shareholder value creation. For healthcare investors evaluating exposure to pharmacy retail, PBM services, and health insurance operations, CVS Revenue represents a comprehensive proxy for the entire integrated healthcare sector.

CVS Revenue by Segment: Financial Breakdown

CVS Revenue Historical Performance and Growth Trajectory

CVS Health’s revenue history demonstrates consistent growth across the past five fiscal years, driven by pharmacy volume increases, insurance premium expansion, and strategic acquisitions. The company generated $268 billion in revenue in 2020, $292 billion in 2021, $322 billion in 2022, and $357.77 billion in 2023, representing compound annual growth rate (CAGR) of 7.6%. This growth trajectory outpaced traditional retail pharmacy growth rates of 2-3% annually, reflecting CVS’s successful diversification into health insurance through Aetna acquisition completed in 2018. Future revenue projections estimate CVS will reach $385-395 billion by 2025, assuming continued Medicare Advantage enrollment growth and specialty pharmacy expansion.

Profitability growth exceeded revenue growth significantly, with net income increasing from $7.18 billion in 2020 to $8.34 billion in 2023 (16.1% total growth) despite revenue growing 33.5%. This margin expansion reflects operational leverage from integrated healthcare operations, cost synergies from Aetna integration, and improved PBM economics. Operating income margins improved from 2.7% in 2022 to 2.3% in 2023 due to accounting changes, but underlying operational performance strengthened substantially. Karen Lynch, CVS Health Chief Executive Officer since February 2021, implemented operational improvements driving profitability growth despite pricing pressures in pharmacy and health insurance markets.

Advantages and Disadvantages of CVS Revenue Model

Advantages of CVS’s Revenue Structure

• Revenue Diversification Across Healthcare Segments — CVS’s multi-channel revenue model spanning pharmacy (76.6%), health insurance (20.5%), and retail services (3.3%) reduces dependence on any single business segment. This diversification provides stability during industry disruptions affecting specific sectors, such as pharmacy reimbursement pressure or health insurance market volatility.
• Vertical Integration and Cost Synergies — Owning both pharmacy operations and health insurance through Aetna creates competitive advantages in drug pricing negotiations and patient care management. CVS captures margins across pharmacy, PBM, and insurance value chain, reducing costs by approximately 3-5% compared to non-integrated competitors. This integrated model enabled CVS to grow net income 101% while growing revenue only 11.1%, demonstrating operational leverage.
• Recurring Premium Revenue Stability — Health Care Benefits segment generated $73.4 billion in 2023 from recurring insurance premiums, creating predictable, high-margin revenue less vulnerable to transactional volatility. Medicare Advantage plans with 4,267 thousand members and Medicaid plans with 2,325 thousand members as of December 31, 2025 provide stable membership and premium growth of 15-20% annually.
• Market Leadership in Specialty Pharmacy — CVS’s specialty pharmacy operations generate higher gross margins (12-15%) compared to community pharmacy (2-3%), improving overall company profitability. Strategic focus on specialty drug distribution for cancer, hepatitis C, HIV, and autoimmune diseases captures high-value medication segments with limited generic competition.
• Pharmacy Network Scale and Convenience Factor — Operating approximately 9,000 retail locations as of December 31, 2025 provides unmatched distribution scale and customer convenience, driving high prescription volumes and front-store traffic. This scale enables CVS to negotiate favorable terms with pharmaceutical manufacturers, insurance companies, and health systems, translating into margin advantages.

Disadvantages and Challenges to CVS Revenue Model

• Pharmacy Reimbursement Pressure and Margin Compression — Community pharmacy gross margins have declined from 2.8% in 2018 to 2.2% in 2023 due to insurance company pressure and generic drug pricing competition. CVS’s heavy dependence on pharmacy revenue (76.6% of total) makes the business vulnerable to further reimbursement pressure from Medicare, Medicaid, and major pharmacy benefit managers.
• Health Insurance Regulatory and Competitive Risks — Health Care Benefits segment faces increasing government scrutiny regarding Medicare Advantage plan commissions, specialty drug distribution conflicts of interest, and pricing transparency requirements. Regulatory changes could reduce Aetna profitability and limit the competitive advantages of vertical integration that CVS’s revenue model depends upon.
• Amazon Pharmacy and E-Commerce Pharmacy Competition — Amazon Pharmacy launched in 2020 and expanded significantly in 2023, capturing market share in mail-order pharmacy and generic drug distribution. This competition directly threatens CVS’s pharmacy revenue, particularly among younger demographics and mail-order prescriptions where convenience and price-based decisions dominate.
• Healthcare Consolidation and Physician Network Integration Risks — Competitors including UnitedHealth Group, Humana, and Walgreens Boots Alliance are increasing physician network ownership and healthcare delivery integration. CVS’s revenue model faces long-term pressure if healthcare consolidation reduces CVS’s competitive advantages in drug pricing and patient care management coordination.
• Macro Healthcare Spending Sensitivity and Economic Cycles — Insurance premium revenue represents 20.5% of CVS’s total revenue but faces risk during economic downturns when employers reduce health plan offerings or reduce benefits. Pharmacy revenue also demonstrates cyclicality with pharmaceutical utilization patterns driven by economic conditions, unemployment rates, and insurance coverage changes.

Key Takeaways

• CVS Health's full-year 2025 total revenues increased to a record high $402.1 billion, up 7.8% compared to prior year.
• Pharmacy operations dominate CVS’s revenue model, contributing $272.6 billion (76.6% of total) through prescription drug distribution, PBM services, and mail-order pharmacy operations.
• Health Care Benefits segment generated total revenues of $143,354 million in the year ended December 31, 2025 through Aetna health insurance plans covering 4,267 thousand Medicare Advantage and 2,325 thousand Medicaid members as of December 31, 2025.
• Vertical integration of pharmacy, PBM, and health insurance operations created operational leverage, enabling net income to grow 101% ($4.15 billion to $8.34 billion) while revenue grew 11.1%.
• Specialty pharmacy operations represent high-margin revenue (12-15% gross margins) and fastest-growing segment, expanding 14.3% to $12.4 billion in 2023 despite comprising only 3.5% of total revenue.
• Pharmacy reimbursement compression, Amazon Pharmacy competition, and healthcare industry consolidation present material risks to CVS’s revenue growth trajectory and profit margins.
• CVS’s integrated healthcare model positioned as recession-resistant due to recurring insurance premium revenue and essential nature of prescription pharmacy services, supporting long-term revenue visibility.

Frequently Asked Questions

What percentage of CVS’s revenue comes from pharmacy operations?

Pharmacy operations generated $272.6 billion in revenue during 2023, representing 76.6% of CVS Health’s total $357.77 billion revenue. This segment includes retail pharmacy sales, pharmacy benefit management services, mail-order pharmacy, and specialty pharmacy operations. The pharmacy segment’s dominance reflects the essential nature of prescription drug distribution and the high-volume, recurring nature of pharmacy transactions supporting stable revenue.

How much did CVS’s net income grow in 2023?

CVS Health’s net income increased 101% in 2023 to $8.34 billion, compared to $4.15 billion in 2022. This exceptional profit growth exceeded revenue growth of 11.1%, demonstrating significant operational leverage and improved business fundamentals. The profit expansion resulted from Aetna integration cost synergies, improved PBM margins, and higher-margin specialty pharmacy revenue growth offsetting community pharmacy reimbursement pressure.

What are the main revenue streams within CVS Health’s business model?

CVS Health generates revenue from four primary sources: pharmacy operations ($272.6 billion), health insurance premiums ($73.4 billion), front store retail merchandise ($11.77 billion), and healthcare services ($5.98 billion). Pharmacy operations include retail pharmacy sales, PBM claim processing, and specialty pharmacy distribution. Health insurance revenue comes from Medicare Advantage, Medicaid, commercial insurance, and specialty insurance plans operated through Aetna subsidiary. This diversified model reduces dependence on any single revenue source and creates competitive advantages through vertical integration.

How has CVS’s revenue grown over the past four years?

CVS Health’s revenue increased from $268 billion in 2020 to $357.77 billion in 2023, representing 33.5% total growth or 7.6% compound annual growth rate (CAGR). Revenue grew $24 billion from 2020 to 2021 (8.2% growth), $30 billion from 2021 to 2022 (10.3% growth), and $35.77 billion from 2022 to 2023 (11.1% growth). This accelerating growth trajectory reflects Aetna health insurance integration benefits, Medicare Advantage enrollment expansion, and specialty pharmacy segment development.

What percentage of CVS’s revenue comes from health insurance?

Health Care Benefits segment generated total revenues of $143,354 million in the year ended December 31, 2025. This segment encompasses Aetna Medicare Advantage plans covering 4,267 thousand members and Medicaid plans covering 2,325 thousand members as of December 31, 2025, commercial insurance products, and specialty insurance offerings. Segment total revenues increased 9.7% for the year ended December 31, 2025 compared to the prior year, primarily driven by increases in the Government business, largely due to the impact of the IRA on the Medicare Part D program.

How does CVS’s vertical integration impact its revenue and profitability?

CVS’s vertical integration of pharmacy, pharmacy benefit management, and health insurance creates significant competitive advantages driving revenue growth and profit expansion. Integration enables CVS to reduce pharmacy costs by 3-5% through direct-to-manufacturer negotiations and patient care management coordination, improving margins compared to non-integrated competitors. The 101% net income growth in 2023 despite 11.1% revenue growth demonstrates operational leverage from vertical integration, where incremental revenue drops through to profit at higher rates due to fully-leveraged cost structures.

What are CVS’s revenue projections for 2024 and 2025?

CVS Health reported total revenues of $402,067 million for the year ended December 31, 2025, compared with $372,809 million for 2024. Health Care Benefits segment revenue is projected to grow 12-15% annually through 2025, driven by Medicare Advantage expansion as baby boomers enter the eligible age cohort. Pharmacy revenue growth is estimated at 6-8% through 2025, reflecting generic drug volume increases, specialty pharmacy expansion, and integrated healthcare network development.

How much revenue does CVS generate from front store and retail merchandise?

CVS’s front store and other operations generated $11.77 billion in revenue during 2023, representing 3.3% of total company revenue. This segment includes over-the-counter medications ($3.8 billion), beauty and personal care products ($4.2 billion), general merchandise ($2.1 billion), and miscellaneous retail revenue ($1.67 billion). While front store revenue represents a small percentage of total revenue, these operations drive customer traffic to pharmacy locations, support higher-margin service offerings, and create engagement opportunities with younger demographics less likely to prioritize pharmacy transactions.